Charles Schwab Investment Management Inc Amylyx Pharmaceuticals, Inc. Call Options Transaction History
Charles Schwab Investment Management Inc
- $429 Billion
- Q1 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding AMLX
# of Institutions
184Shares Held
50.3MCall Options Held
5.84MPut Options Held
2.06M-
Vanguard Group Inc Valley Forge, PA5.35MShares$10.2 Million0.0% of portfolio
-
Black Rock Inc. New York, NY4.47MShares$8.5 Million0.0% of portfolio
-
Goldman Sachs Group Inc New York, NY2.94MShares$5.59 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny2.47MShares$4.7 Million0.0% of portfolio
-
Morgan Stanley New York, NY2.07MShares$3.93 Million0.0% of portfolio
About Amylyx Pharmaceuticals, Inc.
- Ticker AMLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,533,200
- Market Cap $111M
- Description
- Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...